Early-Phase Study of KITE-585 in Resistant Multiple Myeloma
Posted: Thursday, October 14, 2021
Despite the many advances in treatment, patients with multiple myeloma are known to relapse. An article published in the American Journal of Cancer Research highlighted findings from a phase I trial that examined the efficacy of KITE-585, an autologous anti–B-cell maturation (BCMA) chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory multiple myeloma. Robert Z. Orlowski, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that although there was a manageable safety profile with KITE-585, there were limited antitumor responses in patients with the disease.
“The limited antitumor response {with KITE-585] is consistent with the minimal CAR T-cell expansion, cytokine production, and CAR T-cell function observed,” stated Dr. Orlowski and colleagues.
A total of 14 patients received KITE-585, with a median follow-up of 12.0 months. Patients received a flat dose of 3 × 107 to 1 × 109 of KITE-585 CAR T cells in a 3+3 dose-escalation design. The primary endpoint was the incidence of adverse events, which were defined as dose-limiting toxicities. The secondary and exploratory endpoints included efficacy outcomes, incidence of adverse events, levels of KITE-585 in blood, serum cytokines, and incidence of anti-BCMA CAR T-cell antibodies.
Overall findings revealed that no patients experienced dose-limiting toxic events, yet all patients experienced at least one grade ≥ 3 treatment-emergent adverse event and no grade 5 events. Additionally, one patient experienced a partial response, and three patients achieved stable disease. Overall, the median progression-free survival was 1 month, and the median overall survival was 12.2 months.
Disclosure: For full disclosure of the study authors, visit ncbi.nlm.nih.gov.
